Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Summit Therapeutics PLC (SMMT) had Return on Tangible Equity of -57.20% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-221.31M |
|
-- |
|
-- |
|
$226.00M |
|
$-226.00M |
|
$4.68M |
|
$-221.31M |
|
$-221.31M |
|
$-221.31M |
|
$-221.31M |
|
$-221.31M |
|
$-221.31M |
|
$-226.00M |
|
$-225.91M |
|
718.54M |
|
718.54M |
|
$-0.31 |
|
$-0.31 |
|
| Balance Sheet Financials | |
$423.75M |
|
$0.25M |
|
$11.81M |
|
$435.56M |
|
$41.73M |
|
-- |
|
$5.08M |
|
$46.81M |
|
$388.75M |
|
$386.88M |
|
$388.75M |
|
737.63M |
|
| Cash Flow Statement Financials | |
$-142.11M |
|
$-205.34M |
|
$381.23M |
|
$71.42M |
|
$105.19M |
|
$33.76M |
|
$50.98M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-142.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-56.93% |
|
|
Return on Tangible Equity |
-57.20% |
-50.81% |
|
-56.93% |
|
$0.53 |
|
$-0.20 |
|
$-0.20 |
|